Cancer Family
Malignant Genitourinary System Neoplasm
CI-CAN-00000233Explore in graph →
3,549 active trials61 approved drugs295 evidence items
- NCIt
- C156484
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000233Explore in graph →
Clinical trials
15,544 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,963)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02628067 | Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) | active not recruiting | Phase 2 | 1,609 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Sep 22, 2025 | clinicaltrials |
| NCT03814252 | Prospective Clinical Safety and Efficacy Study of Lesion-targeted MRI-TULSA for Localized Prostate Cancer(PRO-TULSA-PC) | active not recruiting | N/A | 62 | Turku University HospitalOTHER_GOV | 1 | Sep 22, 2025 |
| clinicaltrials |
| NCT02194842 | Phase III Radium 223 mCRPC-PEACE III(PEACE III) | active not recruiting | Phase 3 | 446 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 12 | Sep 19, 2025 | clinicaltrials |
| NCT02972060 | ODM-201 vs Androgen Deprivation Therapy in Hormone naïve Prostate Cancer | active not recruiting | Phase 2 | 61 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 4 | Sep 19, 2025 | clinicaltrials |
| NCT03029403 | Phase 2 Study of Pembrolizumab, DPX-Survivac Vaccine and Cyclophosphamide in Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer | active not recruiting | Phase 2 | 47 | University Health Network, TorontoOTHER | 1 | Sep 19, 2025 | clinicaltrials |
| NCT04763915 | Improving Care After Inherited Cancer Testing(IMPACT) | active not recruiting | N/A | 720 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Sep 19, 2025 | clinicaltrials |
| NCT05354440 | Post Marketing Clinical Follow Up of the BioProtect Balloon Implant System(CLP-10441) | active not recruiting | — | 80 | BioProtectINDUSTRY | 5 | Sep 19, 2025 | clinicaltrials |
| NCT06451263 | Nudge to Gynecologic Oncology | active not recruiting | N/A | 20 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Sep 19, 2025 | clinicaltrials |
| NCT06917560 | Serological Autoantibodies in Early Kidney Cancer Diagnosis and Prognosis: A Multicenter Study | active not recruiting | — | 400 | First Affiliated Hospital of Fujian Medical UniversityOTHER | 1 | Sep 18, 2025 | clinicaltrials |
| NCT04253483 | Comparison of High-Dose Rate Brachytherapy and Stereotactic Ablative Radiotherapy as Monotherapy for the Treatment of Localized Prostate Cancer | active not recruiting | Phase 2 | 14 | Rutgers, The State University of New JerseyOTHER | 1 | Sep 17, 2025 | clinicaltrials |
| NCT05133661 | SUCCESS - Feasibility of HPV Testing and Treatment of Pre-cancerous Cervical Cancer Lesions (HPV Study)(HPV) | active not recruiting | — | 17,602 | JhpiegoOTHER | 4 | Sep 17, 2025 | clinicaltrials |
| NCT03647163 | Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 33 | Vyriad, Inc.INDUSTRY | 1 | Sep 16, 2025 | clinicaltrials |
| NCT04511988 | Using Liquid Biopsy in Newly Diagnosed Patients With High Grade Adenocarcinoma of Ovarian Origin, Fallopian Tubes or Primary Peritoneal(BOVARY CE) | active not recruiting | N/A | 20 | Institut de Cancérologie de LorraineOTHER | 1 | Sep 16, 2025 | clinicaltrials |
| NCT02276430 | TACkLE Study - Tackling Adverse Chemotherapy-associated Late Effects(TACkLE) | active not recruiting | — | 939 | University Medical Center GroningenOTHER | 1 | Sep 15, 2025 | clinicaltrials |
| NCT03889119 | Stereotactic Body Radiation Therapy (SBRT) for Prostate Cancer | active not recruiting | N/A | 100 | Hoag Memorial Hospital PresbyterianOTHER | 1 | Sep 15, 2025 | clinicaltrials |
| NCT04163289 | Preventing Toxicity in Renal Cancer Patients Treated With Immunotherapy Using Fecal Microbiota Transplantation(PERFORM) | active not recruiting | Phase 1 | 20 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sOTHER | 1 | Sep 15, 2025 | clinicaltrials |
| NCT05871008 | Integrated Actionable Aging Assessment for Cancer Patients Pilot | active not recruiting | N/A | 35 | University of Colorado, DenverOTHER | 1 | Sep 15, 2025 | clinicaltrials |
| NCT07173140 | Renal Tumour Imaging Using MRI(RIM) | active not recruiting | N/A | 30 | University College, LondonOTHER | 1 | Sep 15, 2025 | clinicaltrials |
| NCT01655836 | High-Dose Rate Brachytherapy and Stereotactic Body Radiation Therapy in Treating Patients With Prostate Cancer | active not recruiting | Phase 1 | 42 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Sep 11, 2025 | clinicaltrials |
| NCT06074510 | PYLARIFY® PET/CT or PET/MRI in Men With Favorable Intermediate Risk (FIR) Prostate Cancer(MIRROR) | active not recruiting | Phase 4 | 274 | Lantheus Medical ImagingINDUSTRY | 1 | Sep 11, 2025 | clinicaltrials |
| NCT03937219 | Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma(COSMIC-313) | active not recruiting | Phase 3 | 855 | ExelixisINDUSTRY | 25 | Sep 10, 2025 | clinicaltrials |
| NCT05653882 | A Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid Tumors | active not recruiting | Phase 1 | 552 | Asher Biotherapeutics, Inc.INDUSTRY | 1 | Sep 10, 2025 | clinicaltrials |
| NCT05845814 | A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04) | active not recruiting | Phase 1 / Phase 2 | 390 | Merck Sharp & Dohme LLCINDUSTRY | 12 | Sep 10, 2025 | clinicaltrials |
| NCT00082706 | Fluorouracil, Leucovorin, Gemcitabine, and Cisplatin in Treating Patients With Metastatic or Unresectable Adenocarcinoma of the Urothelium or Urachal Remnant | active not recruiting | Phase 2 | 46 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 9, 2025 | clinicaltrials |
| NCT01990521 | Prostate Screening Study Using MRI in BRCA Carriers | active not recruiting | N/A | 60 | Toronto Sunnybrook Regional Cancer CentreOTHER | 1 | Sep 9, 2025 | clinicaltrials |
| NCT04906993 | Camrelizumab Combined With Famitinib Malate for Treatment of Recurrent/Metastatic Cervical Cancer | active not recruiting | Phase 3 | 443 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Sep 9, 2025 | clinicaltrials |
| NCT04671693 | A Post-treatment Program to Identify and Manage Complications Related to Oncology or Hematology Treatments in Cancer Survivors.(PASCA) | active not recruiting | N/A | 500 | Centre Leon BerardOTHER | 1 | Sep 5, 2025 | clinicaltrials |
| NCT05462379 | Autologous Heterotopic Fresh Ovarian Graft in Woman With LACC Eligible for Pelvic Radiotherapy Treatment. | active not recruiting | Phase 1 / Phase 2 | 22 | MARILIA ALBANEZI BERTOLAZZIOTHER | 1 | Sep 5, 2025 | clinicaltrials |
| NCT03180034 | Comparing One or Two Doses of the Human Papillomavirus Vaccine for the Prevention of Human Papillomavirus Infection, ESCUDDO Study(ESCUDDO) | active not recruiting | Phase 4 | 27,945 | National Cancer Institute (NCI)NIH | 1 | Sep 4, 2025 | clinicaltrials |
| NCT03317990 | Evaluating the Effects of Frozen Section Technology on Oncological and Functional Outcomes at Radical Prostatectomy.(NeuroSAFEPROOF) | active not recruiting | N/A | 407 | University College, LondonOTHER | 1 | Sep 4, 2025 | clinicaltrials |
| NCT05318573 | A Study to Evaluate Safety, Efficacy of FF-10832 in Combo With Pembrolizumab in Urothelial & Non-small Cell Lung Cancer | active not recruiting | Phase 2 | 120 | Fujifilm Pharmaceuticals U.S.A., Inc.INDUSTRY | 1 | Sep 4, 2025 | clinicaltrials |
| NCT05336786 | Prostate Cancer Diagnosis by Multiparametric Ultrasound (Wholemount) | active not recruiting | Phase 3 | 70 | Thomas Jefferson UniversityOTHER | 2 | Sep 4, 2025 | clinicaltrials |
| NCT07153952 | RT for Adenocarcinoma/Adenosquamous Carcinoma | active not recruiting | Phase 1 / Phase 2 | 60 | Peking Union Medical College HospitalOTHER | 1 | Sep 4, 2025 | clinicaltrials |
| NCT07155759 | Long-term Outcomes of Prostate Cancer Screening(STHLM3MRI_3) | active not recruiting | N/A | 7,500 | Karolinska InstitutetOTHER | 1 | Sep 4, 2025 | clinicaltrials |
| NCT05782400 | Multiomics Approach in Metastatic Clear Renal Cell Carcnoma | active not recruiting | — | 100 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Sep 3, 2025 | clinicaltrials |
| NCT06703437 | Long Acting Neuraxial Peri-prostatic Block in Cancer | active not recruiting | Phase 1 | 12 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Sep 3, 2025 | clinicaltrials |
| NCT05629065 | Pathways to Advance Targeted and Helpful Serious Illness Conversations (PATH-SIC)((PATH-SIC)) | active not recruiting | N/A | 800 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 28, 2025 | clinicaltrials |
| NCT03907852 | Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer | active not recruiting | Phase 1 / Phase 2 | 57 | TCR2 TherapeuticsINDUSTRY | 2 | Aug 27, 2025 | clinicaltrials |
| NCT06127238 | Study of ST-1898 in Advanced Renal Cell Carcinoma | active not recruiting | Phase 1 / Phase 2 | 90 | Beijing Scitech-Mq Pharmaceuticals LimitedINDUSTRY | 1 | Aug 24, 2025 | clinicaltrials |
| NCT06253182 | Psychosexual Educational Partners Program (PEPP)(PEPP) | active not recruiting | N/A | 60 | The University of Tennessee, KnoxvilleOTHER | 1 | Aug 24, 2025 | clinicaltrials |
| NCT03385655 | Prostate Cancer Biomarker Enrichment and Treatment Selection | active not recruiting | Phase 2 | 200 | Canadian Cancer Trials GroupNETWORK | 1 | Aug 21, 2025 | clinicaltrials |
| NCT04319783 | Darolutamide + Consolidation Radiotherapy in Advanced Prostate Cancer Detected by PSMA(DECREASE) | active not recruiting | Phase 2 | 65 | Trans Tasman Radiation Oncology GroupOTHER | 2 | Aug 21, 2025 | clinicaltrials |
| NCT06824259 | The Value of Dual-parametric Magnetic Resonance Combined With Regional Saturation Biopsy in Patients With Suspected Prostate Cancer | active not recruiting | N/A | 400 | Peking University First HospitalOTHER | 1 | Aug 21, 2025 | clinicaltrials |
| NCT04015622 | PROstate Cancer TReatment Optimization Via Analysis of Circulating Tumour DNA(PROTRACT) | active not recruiting | Phase 2 | 100 | British Columbia Cancer AgencyOTHER | 1 | Aug 20, 2025 | clinicaltrials |
| NCT05645237 | HRQOL in Prostate Cancer Patients Treated With Radiotherapy(PRORAD) | active not recruiting | — | 600 | Erasmus Medical CenterOTHER | 1 | Aug 19, 2025 | clinicaltrials |
| NCT06181266 | A Phase 1/1b Study of ZH9 Treatment in Patients With Non-Muscle Invasive Bladder Cancer(PARADIGM-1) | active not recruiting | Phase 1 | 22 | Prokarium LtdINDUSTRY | 1 | Aug 19, 2025 | clinicaltrials |
| NCT01990196 | Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate Cancer | active not recruiting | Phase 2 | 45 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 17, 2025 | clinicaltrials |
| NCT02766543 | Pivotal Study of MRI-guided Transurethral Ultrasound Ablation in Patients With Localized Prostate Cancer(TACT) | active not recruiting | N/A | 150 | Profound Medical Inc.OTHER | 5 | Aug 17, 2025 | clinicaltrials |
| NCT03170960 | Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | active not recruiting | Phase 1 | 914 | ExelixisINDUSTRY | 9 | Aug 17, 2025 | clinicaltrials |
| NCT03630666 | Comparison of Intermittent Androgen Deprivation Therapy With or Without Irradiation Recovery in Prostate Cancer Patients(OLIGOPELVIS2) | active not recruiting | N/A | 256 | Institut Cancerologie de l'OuestOTHER | 1 | Aug 17, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Sep 22, 2025source: clinicaltrials